Biomarkers of mild cognitive impairment and alzheimer's disease

• US 7,851,172 B2
• Filed: 07/25/2006
• Issued: 12/14/2010
• Est. Priority Date: 07/25/2006
• Status: Expired due to Fees

• Current Assignee: University Of Kentucky Research Foundation (University of Kentucky)
• Original Assignee: University Of Kentucky Research Foundation (University of Kentucky)
• Inventors: Lovell, Mark A., Lynn, Bert C.
• Primary Examiner(s): Chernyshev; Olga N
• Application Number:
  US11/459,763
• Publication Number:
  US 20080026405A1
• Time in Patent Office: 1,603 Days
• Field of Search: None
• US Class Current: 435/7.92
• CPC Class Codes: G01N 2800/2821 Alzheimer
• CPC Class Codes: G01N 33/6896 Neurological disorders, e.g. Alzheimer's disease

Abstract

A method for quantifying a neurodegenerative disorder in a patient that includes obtaining a fluid sample from the subject; measuring a protein biomarker complex in said fluid sample and correlating the measurement with mild cognitive impairment or Alzheimer'"'"'s disease status. The biomarkers include those that comprise at least one of a transthyretin protein and/or a prostaglandin-H2 D-isomerase protein, and at least one second, different protein selected from a transthyretin, prostaglandin-H2 D-isomerase, beta-2-microglobulin, cystatin C, superoxide dismutase [Cu—Zn], plasma retinol-binding protein, phosphatidylethanolamine-binding protein, carbonic anhydrase 2, prostaglandin-H2 D-isomerase, and/or serotransferrin protein.

Claims

1. A method for aiding diagnosis of mild cognitive impairment or Alzheimer'"'"'s Disease in an individual, comprising:

(a) obtaining a sample of cerebrospinal fluid from the individual;

(b) measuring an amount of and/or a concentration of a protein biomarker complex that comprises transthyretin and prostaglandin-H2 isomerase in said sample; and

(c) comparing the measured amount and/or concentration to a reference value, wherein a greater measured amount and/or concentration of the biomarker complex as compared to the reference value is indicative of a higher likelihood that the individual is afflicted with mild cognitive impairment or Alzheimer'"'"'s disease, thereby aiding diagnosis of mild cognitive impairment or Alzheimer'"'"'s disease in the individual.

2. The method of claim 1, wherein the reference value is based on a value from each of a plurality of samples, wherein the plurality of samples comprises at least one sample from each of a plurality of individuals afflicted with mild cognitive impairment or Alzheimer'"'"'s disease.

3. The method of claim 1, wherein the reference value is based on a value from one or a plurality of samples obtained from the individual at one or a plurality of earlier points in time.

4. The method of claim 2, wherein the reference value is less than about 5 ng/mL.

5. The method of claim 2, wherein the reference value is about 5 ng/mL.

6. The method of claim 2, wherein the reference value is 5 ng/mL.